trending Market Intelligence /marketintelligence/en/news-insights/trending/MXlAtyOhCLuMHkyMeXi6rQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Aytu BioScience launches $10M private placement

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Aytu BioScience launches $10M private placement

Aytu BioScience Inc. is raising $10 million in a private placement of its series F convertible preferred stock and warrants to buy common stock.

Institutional investors Altium Capital and Armistice Capital jointly participated in the deal.

The shares of preferred stock will be sold at $1,000 per share and are convertible into 1,000 common shares at $1 per share. The preferred shares are also accompanied by warrants to buy up to one common share for each share of common stock convertible from the preferred stock, exercisable at $1.25 per share.

The five-year warrants are exercisable following shareholder approval.

Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent in connection with the offering.

Englewood, Colo.-based Aytu Bioscience develops products for hypogonadism, insomnia and male infertility. The company recently agreed to acquire a portfolio of six prescription products from Cerecor Inc. for an up-front payment of $17 million.